ALDH3A1 and non-small cell lung carcinoma: Finally, we demonstrated in vitro and in vivo that are independent of EGFR and KRAS status, ALDH1 and ALDH3 may be key therapeutic targets for NSCLC either alone or combined with ROS-inducing chemotherapeutic agents.